Literature DB >> 11970980

On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloimmune response.

Gülçin Demirci1, Wenda Gao, Xin Xiao Zheng, Thomas R Malek, Terry B Strom, Xian Chang Li.   

Abstract

Activation and robust expansion of naive T cells often require T cell costimulatory signals and T cell growth factors. However, the precise growth and costimulation requirements for activation and expansion of CD4(+) and CD8(+) T cells in vivo in allograft response are still not clearly defined. In the present study, we critically examined the role of CD28/CD40 ligand (CD40L) costimulation and the common gamma-chain (gamma(c)) signals, a shared signaling component by receptors for all known T cell growth factors (i.e., IL-2, IL-4, IL-7, IL-9, IL-15, IL-21), in activation and expansion of CD4(+) and CD8(+) T cells in the allogeneic hosts. We found that CD28/CD40L costimulation and the gamma(c) signals are differentially involved in proliferation and clonal expansion of CD4(+) and CD8(+) T cells in response to alloantigen stimulation. CD8(+) T cells are highly dependent on the gamma(c) signals for survival, expansion, and functional maturation, whereas in vivo expansion of alloreactive CD4(+) T cells is largely gamma(c) independent. T cell costimulation via CD28 and CD40L, however, is necessary and sufficient for activation and expansion of CD4(+) T cells in vivo. In a skin transplant model, blocking both CD28/CD40L and the gamma(c) pathways induced prolonged skin allograft survival. Our study provides critical insights that the CD4 and CD8 compartments are most likely governed by distinct mechanisms in vivo, and targeting both costimulatory and gamma(c) signals may be highly effective in certain cytopathic conditions involving activation of both CD4(+) and CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11970980      PMCID: PMC3807814          DOI: 10.4049/jimmunol.168.9.4382

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts.

Authors:  M A Williams; J Trambley; J Ha; A B Adams; M M Durham; P Rees; S R Cowan; T C Pearson; C P Larsen
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

Review 2.  Interleukin 15: biology and relevance to human disease.

Authors:  T A Fehniger; M A Caligiuri
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

Review 3.  T cell activation and the cytoskeleton.

Authors:  O Acuto; D Cantrell
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Blocking T-cell costimulation in transplantation: opportunities and challenges.

Authors:  X C Li; T B Strom
Journal:  Transfusion       Date:  2000-02       Impact factor: 3.157

5.  CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection.

Authors:  N D Jones; A Van Maurik; M Hara; B M Spriewald; O Witzke; P J Morris; K J Wood
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 6.  T cell death and transplantation tolerance.

Authors:  X C Li; T B Strom; L A Turka; A D Wells
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

7.  Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells.

Authors:  T R Malek; A Yu; P Scibelli; M G Lichtenheld; E K Codias
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

8.  CD40 ligation enhances IL-15 production by tubular epithelial cells.

Authors:  Michal Weiler; Leonid Kachko; Cidio Chaimovitz; Cees VAN Kooten; Amos Douvdevani
Journal:  J Am Soc Nephrol       Date:  2001-01       Impact factor: 10.121

9.  Gamma chain required for naïve CD4+ T cell survival but not for antigen proliferation.

Authors:  O Lantz; I Grandjean; P Matzinger; J P Di Santo
Journal:  Nat Immunol       Date:  2000-07       Impact factor: 25.606

10.  Role of CD40 ligand and CD28 in induction and maintenance of antiviral CD8+ effector T cell responses.

Authors:  S O Andreasen; J E Christensen; O Marker; A R Thomsen
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

View more
  4 in total

Review 1.  The two faces of heterologous immunity: protection or immunopathology.

Authors:  Shalini Sharma; Paul G Thomas
Journal:  J Leukoc Biol       Date:  2013-11-08       Impact factor: 4.962

Review 2.  Virological and Immunological Outcomes of Coinfections.

Authors:  Naveen Kumar; Shalini Sharma; Sanjay Barua; Bhupendra N Tripathi; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2018-07-05       Impact factor: 26.132

3.  Heterologous immunity provides a potent barrier to transplantation tolerance.

Authors:  Andrew B Adams; Matthew A Williams; Thomas R Jones; Nozomu Shirasugi; Megan M Durham; Susan M Kaech; E John Wherry; Thandi Onami; J Gibson Lanier; Kenneth E Kokko; Thomas C Pearson; Rafi Ahmed; Christian P Larsen
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

4.  IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response.

Authors:  Alessandra Petrelli; Michele Carvello; Andrea Vergani; Kang Mi Lee; Sara Tezza; Ming Du; Sonja Kleffel; Liu Chengwen; Bechara G Mfarrej; Patrick Hwu; Antonio Secchi; Warren J Leonard; Deborah Young; Mohamed H Sayegh; James F Markmann; Allan J Zajac; Paolo Fiorina
Journal:  Diabetes       Date:  2011-10-19       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.